Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism

JAMA

Volumn 312, Issue 2, 2014, Pages 187-188

  Scheller, Nikolai Madrid ^a   Pasternak, Björn ^a   Svanström, Henrik ^a   Hviid, Anders ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CONTRACEPTIVE AGENT; WART VIRUS VACCINE;

ADULT; AGE; ARTICLE; CHILD; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; PRIORITY JOURNAL; RISK FACTOR; VACCINATION; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; CHILD; DENMARK; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; REGISTRIES; RETROSPECTIVE STUDIES; RISK; TIME FACTORS; VACCINATION; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84903886335     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.2198     Document Type: Article

References (6)

1. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302(7):750-757.
2. Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011;29(46):8279-8284.
3. Siegrist CA. Autoimmune diseases after adolescent or adult immunization: what should we expect? CMAJ. 2007;177(11):1352-1354.
4. Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013;347:f5906.
5. Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics. 1995;51(1):228-235.
6. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med. 2006;25(10): 1768-1797.